Investment Analysts’ Weekly Ratings Changes for Tempus AI (TEM)

Tempus AI (NASDAQ: TEM) recently received a number of ratings updates from brokerages and research firms:

• 3/11/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 3/9/2026 – Tempus AI had its price target raised by HC Wainwright from $89.00 to $95.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Tempus AI had its price target lowered by Morgan Stanley from $85.00 to $70.00. They now have an “overweight” rating on the stock.
• 2/28/2026 – Tempus AI was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/25/2026 – Tempus AI was given a new $60.00 price target by Stifel Nicolaus.
• 2/25/2026 – Tempus AI had its price target lowered by JPMorgan Chase & Co. from $80.00 to $60.00. They now have a “neutral” rating on the stock.
• 2/25/2026 – Tempus AI had its price target lowered by Needham & Company LLC from $100.00 to $75.00. They now have a “buy” rating on the stock.
• 2/25/2026 – Tempus AI had its price target lowered by BTIG Research from $105.00 to $90.00. They now have a “buy” rating on the stock.
• 2/19/2026 – Tempus AI is now covered by Mizuho. They set an “outperform” rating and a $100.00 price target on the stock.
• 2/19/2026 – Tempus AI is now covered by Mizuho. They set an “outperform” rating and a $100.00 price target on the stock.
• 2/17/2026 – Tempus AI is now covered by Robert W. Baird. They set an “outperform” rating and a $59.00 price target on the stock.
• 2/17/2026 – Tempus AI is now covered by Robert W. Baird. They set an “outperform” rating and a $59.00 price target on the stock.
• 1/22/2026 – Tempus AI had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In related news, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the transaction, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total transaction of $562,445.52. Following the sale, the executive vice president directly owned 79,816 shares in the company, valued at approximately $4,743,464.88. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 568,841 shares of company stock valued at $35,507,274. Insiders own 26.27% of the company’s stock.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.